We’ve used TipRanks’ Top Analysts Stocks tool to search our database for the best stocks to buy in today’s highly volatile markets. While looking …
B.Riley FBR analyst George Zavoico is out today with a bullish note on shares of Novavax (NASDAQ:NVAX), after the clinical-stage vaccine-maker announced last week that 4,600 …
Shares of Novavax (NASDAQ:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, tumbled nearly 17% during Thursday’s pre-market …
Novavax, Inc. (NASDAQ:NVAX) provided a corporate update and announced its financial results for the fourth quarter and twelve months ended December 31, 2017.
Brace yourself. Novavax, Inc.
Wall Street is paying attention to FBR’s George Zavoico’s surge in enthusiasm on Novavax’s prospects.
Cantor’s William Tanner is not thrilled as he joins a disgruntled Street saying goodbye to what could have been a meaningful catalyst for NVAX shares before the end of 2017: NanoFlu vaccine top-line data.
Novavax, Inc. (NASDAQ:NVAX) announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal …
Novavax, Inc. (NASDAQ:NVAX) announced that Barclay A.
Novavax, Inc. (NASDAQ:NVAX) announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including …
